

AMENDMENT TO THE CLAIMS

Claims 1-20 (cancelled)

E1  
Claim 21. (<sup>Currently</sup> Previously Amended) An isolated polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) with glucosyltransferase activity, consisting essentially of approximately the first 1020 N-terminal amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO: 6.

Claim 22. (Currently Amended) A compound ~~comprising~~ consisting of a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) according to SEQ ID NO: 1 or a portion thereof, the compound having (i) a glucosyltransferase activity domain, and (ii) a target cell specific binding domain which permits the compound to bind to a target cell.

Claim 23. (Currently Amended) A compound ~~comprising~~ consisting of a polypeptide fragment of *Clostridium sordellii* lethal Toxin (LT) consisting essentially of approximately the first 1020 amino acids of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT) as defined by SEQ ID NO: 1 or a portion thereof, the compound having (i) a glucosyltransferase activity domain, (ii) a target cell specific binding domain, which domain causes the compound to bind to a target cell, and (iii) ~~iv~~ a translocation domain for translocating a catalytic domain of *Clostridium sordellii* lethal Toxin (LT) from the exterior of a cell into the interior of said cell.

Claim 24. (Previously Added) A compound according to claim 23, wherein the translocation domain consists essentially of approximately the N-terminal amino acids 1021-1700 of the amino acid sequence of *Clostridium sordellii* lethal Toxin (LT).

Claim 25. (Previously Added) A compound according to one of claims 22 to 24, wherein the target cell specific binding domain is an antibody or an antigen binding fragment thereof.

Claim 26. (Currently Amended) A composition ~~comprising~~ consisting of a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

Claim 27. (Currently Amended) A composition ~~comprising~~ consisting of a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.

Claim 28. (Previously Added) A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to one of claims 22 to 24 and a pharmaceutically acceptable adjuvant or carrier.

Claim 29. (Previously Added) A method of manufacturing a composition, said method comprising the steps of bringing together a compound according to claim 25 and a pharmaceutically acceptable adjuvant or carrier.